Search

Displaying results 2091 - 2100 of 4590 in total
  1. Drug

    Interferon gamma-1b

    go.drugbank.com/drugs/DB00033
    ApprovedInvestigational

    Purification of the product is achieved by conventional column chromatography. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.

  2. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    [A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

  3. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  4. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the

  5. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.

  6. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

  7. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub

  8. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.

  9. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]

  10. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    It is marketed by AstraZeneca under the trade name Iressa.